##  [China: Conditional Drug Approval System Update](/mandate/china-conditional-drug-approval-system-update) 

March 30, 2026

The National Medical Products Administration (NMPA) has initiated enhancements to its conditional drug approval system, following a high-level meeting led by Li Li. The initiative aims to accelerate the availability of critical therapies, particularly for patients with unmet medical needs such as in oncology.

### Key Highlights:

- **Policy Focus:**
    - Strengthening and refining the conditional approval pathway to improve access to urgently needed drugs.
- **Scope:**
    - Applicable to conditionally approved drugs, including innovative therapies and select generics.
- **Key Reforms / Provisions:**
    - **Revised Working Procedures**: Approval of the “Working Procedures for the Review and Approval of Conditional Drug Marketing Applications (Revised Draft)” to standardize processes.
    - **Clearer Approval Standards**: Enhanced clarity on eligibility and evaluation criteria for conditional approvals.
    - **Post-Marketing Commitments**: Defined timelines and requirements for post-marketing studies to confirm safety and efficacy.
    - **Lifecycle Management**: New provisions covering re-registration, generic drug applications, and marketing authorization holder changes.
    - **Focus on Critical Therapies**: Continued prioritization of drugs addressing serious or life-threatening conditions, especially in oncology.
- **Regulatory Goals:**
    - Accelerate patient access to life-saving treatments.
    - Align with global regulatory practices and evolving innovation trends.
    - Strengthen compliance, oversight, and patient protection mechanisms.
    - Improve coordination with industry and address key implementation challenges.



[Consult Now](/webform/consult%0A?url=https://preprod.freyrsolutions.com/markdownify/node/13093)



Source

<https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/yphyxx/20260330175015196.html>

 

 

Select Mandate HA

[NMPA](/mandate-by-ha/nmpa)

 

Select Mandate Function

[Regulatory Affairs](/mandate-by-function/regulatory-affairs)